HHS Floats Expedited IND Pilot to Accelerate U.S. Clinical Research

The U.S. Department of Health and Human Services (HHS) has unveiled an ambitious initiative aimed at restoring America's leadership in clinical research by significantly shortening the timeline from drug discovery to first-in-human (FIH) clinical trials.  

Announced as part of Operation TrailBlazer, the initiative includes a proposed Expedited Investigational New Drug (IND) Pilot Program led by the U.S. Food and Drug Administration (FDA), along with several complementary reforms designed to modernize clinical development. 

If implemented, the proposal could represent one of the most significant changes to early-stage drug development in decades - and one with relevance for Michigan's growing life sciences ecosystem. 

A New Model for Early Clinical Development 

At the heart of the proposal is a pilot program that would allow drug developers to partner with qualified research institutions - including academic medical centers, contract research organizations (CROs), healthcare networks, and regulatory experts - to collaboratively prepare and review Phase I IND submissions before they reach FDA. 

Rather than relying solely on the traditional sequential review process, sponsors would submit information through a rolling IND platform, enabling FDA reviewers to assess portions of an application as they are completed. The goal is to improve submission quality, reduce clinical holds, and move promising therapies into first-in-human studies more quickly while maintaining patient safety. 

According to FDA, the program is intended to be especially valuable for smaller biotechnology companies and academic innovators that may lack extensive in-house regulatory resources. 

Addressing a Competitive Challenge 

HHS says the initiative responds to an increasingly competitive global clinical research environment. 

According to the agency, lengthy regulatory timelines have contributed to a growing migration of early-stage clinical research overseas, particularly to China, where sponsors often initiate first-in-human studies more rapidly. HHS estimates that unnecessary regulatory friction can delay U.S. early-stage development by six to twelve months, potentially slowing investment and patient access to innovative therapies. 

"America should be the best place in the world to develop new medicines," HHS Secretary Robert F. Kennedy Jr. said in announcing the initiative. "We have built a system that drives too much clinical research overseas." 

Operation TrailBlazer Extends Beyond the IND Pilot 

The proposed IND pilot is only one component of Operation TrailBlazer, a coordinated effort involving multiple HHS agencies to streamline clinical development across the entire drug development lifecycle. 

Other planned initiatives include: 

• Updated FDA guidance clarifying that, in appropriate circumstances, a single well-controlled pivotal clinical trial supported by confirmatory evidence may provide sufficient evidence of effectiveness for drug approval. 

• Expanded use of innovative clinical trial designs, including master protocols, basket trials, umbrella trials, and platform studies. 

• Greater NIH investment in AI-enabled tools, human cell-based models, and real-world data to improve trial efficiency. 

• Improved patient recruitment, including exploration of electronic health record tools that can identify eligible clinical trial participants during routine care. 

• Potential updates to federal anti-kickback safe harbor rules related to compensation for clinical trial participants. 

Why It Matters for Michigan 

Michigan's life sciences sector includes a growing number of startup biotechnology companies, university spinouts, CROs, and academic medical centers that frequently encounter regulatory complexity during early clinical development. 

If successfully implemented, the proposed pilot could provide several potential benefits: 

• Faster transition from preclinical research into human studies. 

• Reduced regulatory uncertainty for emerging companies. 

• Greater opportunities for Michigan academic medical centers and research institutions to serve as Qualified Research Institutions (QRIs) under the pilot. 

• Increased attractiveness of the U.S., and states like Michigan, as destinations for early-stage clinical investment. 

Organizations such as the University of Michigan, Michigan State University, Wayne State University, Corewell Health, Henry Ford Health, and Michigan-based CROs may be well positioned to participate should the pilot move forward. 

Public Comment Period Now Open 

FDA has opened a public docket requesting feedback on the proposed Expedited IND Pilot Program. The agency is seeking input on program design, eligibility criteria for participating research institutions, operational workflows, and safeguards to ensure scientific rigor and patient protection. 

Comments are due July 22, 2026, after which FDA will evaluate stakeholder feedback before determining whether and how to launch the pilot. 

For Michigan's life sciences community, the proposal signals continued federal interest in modernizing clinical research infrastructure and strengthening U.S. competitiveness in biomedical innovation. Whether the pilot ultimately delivers on its promise will depend on balancing greater efficiency with FDA's longstanding commitment to safety, scientific rigor, and public trust.